Scholarlink

<p>Using engineering biology to perform complex chemical synthesis offers a sustainable alternative to traditional processes that rely on finite fossil resources. A growing opportunity within this field lies in reclaiming carbon embedded in industrial and post-consumer waste—carbon otherwise lost to landfill, incineration or pollution. Here we report the bio-upcycling of poly(ethylene terephthalate) (PET) plastic waste into levodopa (<span>l</span>-DOPA), a frontline medication for Parkinson’s disease, using engineered <i>Escherichia coli</i>. Two key bottlenecks—substrate import and feedback inhibition by the intermediate protocatechuate—were addressed through heterologous transporter expression and functional pathway separation across two microbial strains. To further improve sustainability, and as a proof-of-concept, <i>Chlamydomonas reinhardtii</i> was used to capture CO<sub>2</sub> released during catechol generation. The resulting bioprocess operates under mild, aqueous conditions and achieves high <span>l</span>-DOPA titres (5.0 g l<sup>−1</sup>), with isolated product obtained at preparative scale from both industrial PET waste and a single post-consumer plastic bottle. This work demonstrates how engineering biology can transform plastic-derived aromatic monomers into high-value pharmaceuticals for the treatment of neurological disease in humans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microbial upcycling of plastic waste to levodopa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月16日

查看全文
  • Benjamin Royer,
  • Yuta Era,
  • Marcos Valenzuela-Ortega,
  • Thomas W. Thorpe,
  • Connor L. Trotter,
  • Kitty Clouston,
  • John F. C. Steele,
  • Nicoll Zeballos,
  • Eugene Shrimpton-Phoenix,
  • Bhumrapee Eiamthong,
  • Chayasith Uttamapinant,
  • Christopher W. Wood,
  • Stephen Wallace

摘要

Using engineering biology to perform complex chemical synthesis offers a sustainable alternative to traditional processes that rely on finite fossil resources. A growing opportunity within this field lies in reclaiming carbon embedded in industrial and post-consumer waste—carbon otherwise lost to landfill, incineration or pollution. Here we report the bio-upcycling of poly(ethylene terephthalate) (PET) plastic waste into levodopa (l-DOPA), a frontline medication for Parkinson’s disease, using engineered Escherichia coli. Two key bottlenecks—substrate import and feedback inhibition by the intermediate protocatechuate—were addressed through heterologous transporter expression and functional pathway separation across two microbial strains. To further improve sustainability, and as a proof-of-concept, Chlamydomonas reinhardtii was used to capture CO2 released during catechol generation. The resulting bioprocess operates under mild, aqueous conditions and achieves high l-DOPA titres (5.0 g l−1), with isolated product obtained at preparative scale from both industrial PET waste and a single post-consumer plastic bottle. This work demonstrates how engineering biology can transform plastic-derived aromatic monomers into high-value pharmaceuticals for the treatment of neurological disease in humans.